Results 91 to 100 of about 7,789 (204)

Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND

RMD Open
Objective To evaluate the long-term sustainability of response to the Janus kinase inhibitor upadacitinib among patients with rheumatoid arthritis and an inadequate response or intolerance to biological disease-modifying antirheumatic drugs (bDMARD-IR ...
Ronald F van Vollenhoven, Roy Fleischmann, Stephen Hall, Yanna Song, Sebastian Meerwein, Alvin F Wells, Oishi Tanjinatus   +6 more
doaj   +1 more source

Upadacitinib for the treatment of psoriatic arthritis [PDF]

, 2023
Diogo Fonsêca, Miguel Nogueira, Tiago Torres   +2 more
openalex   +1 more source

Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis

Clinical and Translational Science
Upadacitinib is an orally administered, selective, Janus kinase inhibitor that is approved for several auto‐immune conditions, such as axial spondyloarthritis, an inflammatory rheumatic disease that includes ankylosing spondylitis (AS) and non ...
Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In‐Ho Song, Peter Wung, Wei Liu, Mohamed‐Eslam F. Mohamed   +6 more
doaj   +1 more source

P638 Efficacy of Induction upadacitinib Therapy in Chinese Patients with Moderately to Severely Active Crohn’s Disease [PDF]

M Chen, Xiang Gao, Qian Cao, X Zhang, Yuchen Chen, Xu Hou, Jie Zhong, Yang Sun, X Phaleng   +8 more
openalex   +1 more source

Refractory Lichen Amyloidosis Coexisting With Atopic Dermatitis Responsive to Sequential Janus Kinase Inhibitor Therapy: Upadacitinib Followed by Abrocitinib

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 4, April 2026.
Yu‐Ting Tsai, Jui Lan, Shang‐Hung Lin   +2 more
wiley   +1 more source

Off-label use of upadacitinib in dermatology: a review

Journal of Dermatological Treatment
Objectives Upadacitinib, a selective JAK1 inhibitor, is approved for the treatment of atopic dermatitis but is increasingly used off-label in dermatology.
Hongtao Yu, Junkai Zhu, Xiaoli Ni, Kaiyu Yu, Zhen Mu   +4 more
doaj   +1 more source

Oral Jak Inhibitor Upadacitinib Use in Treatment of Pemphigus Foliaceus

, 2023
Sophie Guénin, Syed Arbab Shah, Mark Lebwohl   +2 more
openalex   +2 more sources

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials [PDF]

, 2021
Gerd R Burmester, Kevin Winthrop, Ricardo Blanco, Peter Nash, Philippe Goupille, Valderílio Feijó Azevedo, Carlo Salvarani, Andrea Rubbert‐Roth, Elizabeth R. Lesser, Ralph Lippe, Apinya Lertratanakul, R. Mccaskill, John Liu, Eric Ruderman   +13 more
openalex   +1 more source

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study

Arthritis Research & Therapy
Background The efficacy and safety of upadacitinib in patients with ankylosing spondylitis (AS) and inadequate response/intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR) were evaluated through 1 year in the SELECT-AXIS 2 study ...
Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert Davies Inman, Hideto Kameda, Walter Peter Maksymowych, Ivan Lagunes-Galindo, Xianwei Bu, Peter Wung, Koji Kato, Anna Shmagel, Atul Deodhar   +11 more
doaj   +1 more source

MODULAR GENE EXPRESSION CHANGES IN THE SLEEK PHASE 2 STUDY OF UPADACITINIB AND ABBV-599 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS [PDF]

Kristin M. D’Silva, Michelle D. Catalina, Ioan Filip, Archana Iyer, Peter Wung, Marie‐Claude Gaudreau, Joan T. Merrill   +6 more
openalex   +1 more source